Related Experiment Video

Updated: Jul 7, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.0K

Cell type-specific induction of ferroptosis to boost antitumor immunity

Jiao Liu1, Jingbo Li2, Rui Kang3

  • 1DAMP Lab, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Oncoimmunology
|December 21, 2023
PubMed

Insights

This study introduces N6F11, a novel compound that selectively triggers ferroptosis in cancer cells. This approach avoids suppressing antitumor immunity, offering a new strategy for cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Traditional ferroptosis inducers often impair the immune system's ability to fight cancer.
  • There is a need for ferroptosis activators that enhance, rather than suppress, antitumor immunity.

Purpose of the Study:

  • To discover a novel small molecule compound that selectively induces ferroptosis in cancer cells.
  • To evaluate the compound's effect on antitumor immunity.
  • To establish a safe and effective strategy for ferroptosis-driven cancer immunotherapy.

Main Methods:

  • Utilized a small molecule compound, N6F11.
  • Investigated the mechanism of N6F11-induced ferroptosis, focusing on TRIM25-mediated GPX4 degradation.
  • Assessed the impact of N6F11 on cancer cells and immune cells in vitro and in vivo.

Main Results:

  • N6F11 selectively induces ferroptosis in cancer cells.
  • The compound targets TRIM25 to mediate GPX4 degradation specifically in malignant cells.
  • Immune cells remain unaffected, preserving antitumor immune responses.

Conclusions:

  • N6F11 represents a breakthrough in cancer therapy by selectively activating ferroptosis.
  • This selective approach overcomes the immunosuppressive effects of conventional ferroptosis activators.
  • N6F11 offers a promising strategy to potentiate ferroptosis-mediated antitumor immunity.
Keywords:
Drug discoveryGPX4TRIM25ferroptosisimmunotherapy

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.0K
Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

935

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.5K